Comparison of MRD detection by multiparameter flow cytometry among EuroFlow, Kameda-flow and SRL-flow methods

Comparison of MRD detection by multiparameter flow cytometry among EuroFlow, Kameda-flow and SRL-flow methods - Comparison of MRD detection by multiparameter flow cytometry

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029367

Enrollment

Registered

2017-10-10

Start date

2017-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with symptomatic multiple myeloma by IMWG criteria who achieved at least partial response (PR).

Exclusion criteria

Exclusion criteria: patients who are incapacitated are excluded.

Design outcomes

Primary

Measure	Time frame
Correlation of minimal residual disease (MRD) levels among EuroFlow, Kameda-flow and SRL-flow methods	—

Secondary

Measure	Time frame
1) 1-year and 3-year progression-free survival (PFS) after MRD assessment. 2) 1-year and 3-year overall survival (OS) after MRD assessment. 3) MRD negativity	—

Countries

Japan

Contacts

Public ContactHiroyuki Takamatsu

Kanazawa University Hematology/Respiratory Medicine

takamaz@staff.kanazawa-u.ac.jp076-265-2276

Outcome results